Aileron Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
RNTX$0.62+1.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $12,042 | $17,313 |
| Prepaid expenses and other current assets | 697 | 882 |
| Restricted cash | 25 | 25 |
| Operating lease, right-of-use asset, current portion | — | 46 |
| Total current assets | 12,764 | 18,266 |
| Property and equipment, net | 6 | 19 |
| Goodwill | 6,330 | 6,330 |
| Intangible assets | 79,200 | 79,200 |
| Other non-current assets | 892 | 2,193 |
| Total assets | $99,192 | $106,008 |
| Liabilities, Convertible Preferred Stock and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,156 | $1,190 |
| Accrued expenses and other current liabilities | 2,376 | 3,147 |
| Operating lease liabilities, current portion | — | 48 |
| Total current liabilities | 4,532 | 4,385 |
| Deferred tax liability | 3,326 | 3,326 |
| Total liabilities | 7,858 | 7,711 |
| Commitments and contingencies (Note 15) | ||
| Convertible preferred stock, $0.001 par value, 5,000,000 shares authorized at March 31, 2024 and at December 31, 2023; 24,610 shares issued and 12,653 shares outstanding at March 31, 2024 and 24,610 shares issued and outstanding at December 31, 2023 | 46,584 | 91,410 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized at March 31, 2024 and 45,000,000 at December 31, 2023; 16,842,512 shares and 4,885,512 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 103 | 91 |
| Additional paid-in capital | $340,340 | $295,376 |
| Accumulated other comprehensive loss | (63) | (63) |
| Accumulated deficit | (295,630) | (288,517) |
| Total liabilities, convertible preferred stock and stockholders’ equity | $99,192 | $106,008 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.